Open AccessStudi Docking Molekular Senyawa Turunan Kuinolin Terhadap Reseptor Estrogen-?
Author(s) -
Mohammad Rizki Fadhil Pratama
Publication year - 2016
Publication title -
jurnal surya medika
Language(s) - English
Resource type - Journals
eISSN - 2655-2051
pISSN - 2460-7266
DOI - 10.33084/jsm.v2i1.215
Subject(s) - quinoline , chemistry , estrogen receptor , docking (animal) , estrogen , stereochemistry , breast cancer , medicine , cancer , organic chemistry , nursing
Estrogen-a (ER-a) is the main target for ER + therapy. Inhibition of ER-a is known to slow the proliferation of ER + breast cancer cells. Quinoline derivatives are known to have anticancer activity by inhibiting several types of receptors. It is not known whether quinoline can inhibit ER-a. This study aims to determine the interaction between ER-a with quinoline derivative compounds. Molecular docking of ER-a showed that quinine gave the most negative bond-free energy and the smallest inhibition constant, respectively -8.73 kcal/mol and 0.398 M. These results provide predictions that quinine has activity as an ER-a inhibitor and has the potential to be developed in the treatment of ER + breast cancer. However, the affinity shown by quinine was lower than that of 4-hydroxytamoxifen, a potent inhibitor of ER-a.